Wall Street has long favored complexity—until it doesn’t. This Friday, May 1 (8 a.m. PT / 11 a.m. ET), Tribe Public (www.TribePublic.com) is inviting all interested parties to spend ~30 minutes exploring a simpler path forward in diabetes care, as Modular Medical (NASDAQ: MODD) CEO Jeb Besser takes the virtual stage for a focused presentation and live Q&A.
For those already registered, the seat is secured. For those still circling the idea, consider this your nudge: capacity is capped at 500 attendees, and interest is tracking accordingly. Registration remains open at modd-may-watch.tribepublic.com—for now. Registration is at the following link: MODD-May-Watch.TribePublic.com.
From FDA Clearance to Commercial Countdown
Fresh off its April 9, 2026 FDA 510(k) clearance, Modular Medical is entering a pivotal stretch. The company’s next-generation Pivot tubeless insulin patch pump is now cleared for market, with initial shipments expected by the end of Q2 2026.
The significance here isn’t just regulatory—it’s strategic. In a market historically dominated by feature-rich (and often user-intensive) insulin delivery systems, Modular Medical is betting on a different thesis: that simplicity, affordability, and accessibility can unlock a much larger patient population that represents an approximately $3B market sized opportunity.
The Pivot system reflects that philosophy. It combines a two-part design with a removable 3 mL reservoir, disposable battery, and smartphone connectivity—delivering insulin without the tubing, training burden, or lifestyle friction that have traditionally limited adoption. In industry terms, it targets the “almost-pumper”—patients who might benefit from insulin pumps but have opted out due to complexity or cost.
A Founder’s Blueprint, A Market’s Opportunity
The company’s roots trace back to Paul DiPerna, a veteran medical device engineer best known as the founder of Tandem Diabetes Care (NASDAQ: TNDM) and the architect behind its t:slim insulin pump. That lineage offers both technical credibility and a subtle reminder: disruption in diabetes tech tends to come from those who’ve built it before.
Now, with CEO Jeb Besser at the helm—a capital markets veteran with over 25 years of experience advising more than 100 public companies—Modular Medical is transitioning from development story to commercial execution.
Besser’s dual role as CEO and longtime strategic advisor (and managing member of the company’s largest shareholder) places him at an interesting intersection of operator and investor—an alignment Wall Street typically views favorably, provided execution follows narrative.
The 30-Minute Edge
Tribe Public’s format reflects the realities of modern investing: concise, direct, and accessible. The event will feature a short presentation followed by a 5–10 minute Q&A, all wrapped in roughly half an hour.
Attendees can submit questions in advance to research@tribepublic.com or pose them live during the session—an increasingly valuable opportunity as investors look to parse not just the technology, but the go-to-market strategy, reimbursement dynamics, and competitive positioning in a rapidly evolving diabetes care landscape.
Why It Matters Now
The global diabetes device market continues to expand, driven by rising prevalence, aging populations, and growing demand for patient-friendly technologies. Yet adoption gaps persist—particularly among patients who find current solutions too complex or costly.
Modular Medical’s approach—“diabetes care for the rest of us”—is as much a market thesis as it is a product tagline. If the company can successfully bridge that gap, it could expand the addressable market rather than simply compete within it.
That’s the kind of narrative Wall Street tends to reward: not just innovation, but inclusion.
Final Call: Seats Are Limited
Tribe Members have already begun filling the virtual room, underscoring the continued appetite for early-stage medical device stories with near-term catalysts.
For those looking to stay ahead of the curve—or at least keep pace with it—this Friday’s session offers a timely opportunity to hear directly from leadership as Modular Medical moves from FDA milestone to commercial reality.
Tribe Public (www.TribePublic.com) aggregates the voice of consumers & investors in order to attract the management teams from the world’s most interesting and groundbreaking companies to present at Corporate Sponsored RSVP-Only Tribe Public CEO Presentation and Q&A Luncheon, Dinner, Speaking Engagement & Webinar-Based Events.
They now have members that span across 31 countries and and we are now hosting events across our 41 Tribe Event Venues in the United States that are regularly learning with us.
Tribe members include Portfolio Managers from large and small funds, Registered Investment Advisors, Family Offices, Accredited Investors, Business Owners, Retail Traders, Brokers, Sell-side Analysts, Entrepreneurs & Members of Media.
Apple (AAPL) and Caterpillar (CAT) just turned an ordinary earnings day into a masterclass in corporate reinvention, with one eye on cash flows and the other on AI-fueled futures.
From iPhones to “iCEO”: Apple’s Earnings Sideshow
On paper, Apple’s upcoming quarterly report should be the main event: Wall Street is bracing for a 19% jump in earnings and a 15% rise in revenue, powered by healthier iPhone and services trends. Yet this season, the income statement is the opening act, and the real headliner is John Ternus, the incoming CEO whose mandate begins September 1. In a market that usually obsesses over gross margin to the second decimal place, investors are suddenly more interested in body language on the conference call than in basis points.
Apple’s script has flipped: the company is still printing record numbers—recently reporting quarterly revenue of roughly $143.8 billion with earnings per share up about 19% year over year—but the Street is now asking what the next act looks like under new leadership. The backdrop is hardly serene, with rising component costs, pricier memory chips, and a macro environment shaped by geopolitical tension and a hyper-competitive AI race that is minting winners and losers by the week. The twist is that Apple, long viewed as a steady compounder, is entering a CEO transition just as tech peers are racing ahead with 20%-plus revenue growth, putting gentle pressure on Cupertino to prove it can still set the tempo, not just keep the beat.finance.
The New Boss and the Foldable Future
Tim Cook’s decision to shift into an executive chairman role after more than a decade at the helm has transformed what would have been a routine earnings checkpoint into a referendum on Apple’s next decade. John Ternus, until now better known to hardware engineers than to headline writers, inherits a company rumored to be lining up marquee launches, including a foldable iPhone that might finally give consumers a fresh reason to upgrade rather than just squint at incremental camera bumps. Analysts are watching to see whether Ternus leans into hardware innovation, doubles down on the high-margin services engine, or quietly turns Apple into one of the world’s most profitable AI infrastructure companies without ever saying “AI” three times fast on the call.
Expect investors to parse every hint around component costs, especially memory, which has been marching higher and threatening to nibble at margins just as top-line growth improves. With Apple’s stock down about 1% year to date—after a relatively modest 8.6% gain in 2025, trailing both the Nasdaq 100 and the S&P 500—Wall Street is looking for reassurance that the Ternus era will be about more than just stretching the iPhone franchise another generation. If Cook was the architect of Apple-as-dividend aristocrat, Ternus is being cast, fairly or not, as the showrunner who must prove that even a $2 trillion company can still surprise its audience.
Caterpillar’s Quarter: Heavy Iron, Light Footwork
While Apple debates its philosophical relationship with gravity, Caterpillar is busy digging into it—and apparently charging a premium for the privilege. Analysts had penciled in first-quarter 2026 revenue of about $16.4 billion and earnings per share in the mid-$4 range, assuming a healthy but not heroic upswing in demand. Instead, Caterpillar roared in with roughly $17.4 billion in revenue, a 22.2% year-on-year surge and a solid beat versus expectations, reminding investors that “old economy” doesn’t mean “slow-growth” when your machines are the shovel set for the world’s infrastructure and data-center gold rush.
Behind the headline numbers sits a familiar story of pricing power, backlog strength, and disciplined operations, even as costs and tariffs loom in the background like uninvited guests at an otherwise well-catered earnings party. Consensus heading into the print called for mid-teens revenue growth and high-single-digit EPS expansion, with a modest squeeze in operating margin from around 18.3% to 18.2% as input costs crept higher. Instead, Caterpillar’s performance signaled that the company is learning to pass through inflation, manage tariffs, and still keep its profitability gears well-oiled, validating the thesis that this is no longer just a cyclical industrial, but a capital-efficiency story with structural demand at its back.
When Dirt Meets Data: CAT as Accidental AI Play
In an era when every company with a server claims to be an AI stock, Caterpillar has stumbled into the theme the old-fashioned way: by selling the hardware that helps build the physical world AI actually needs. Data centers, renewable projects, grid upgrades, and mining expansions all require power and earthmoving equipment, and recent quarters have seen Caterpillar’s power and energy-related businesses deliver double-digit growth and strong margins. In a recent period, P&E revenue climbed around 23% year over year to roughly $9.4 billion, with segment profits bolstered by nearly 20% margins, suggesting that CAT’s “AI adjacency” is less about GPUs and more about generators, engines, and the diesel that keeps the cloud humming.
The Street has noticed: earnings expectations for the broader 2026–2027 window imply EPS growth near or above 20% annually, underpinned by infrastructure spending, energy transition projects, and the persistent need to move rock from Point A to Point B. That makes CAT one of the more unintuitive beneficiaries of the AI wave, quietly monetizing the groundwork—literally—for a world that wants to train larger models while also constructing new transmission lines and rebuilding highways. For investors conditioned to think of “platforms” as software moats, Caterpillar offers a different kind of platform: a global installed base of machines, parts, and services that turns capex cycles into recurring revenue.
Two Blue Chips, One Market Mood
Apple and Caterpillar now sit on opposite ends of the modern equity narrative: one a tech titan wrestling with leadership transition and AI expectations, the other an industrial stalwart turning infrastructure, energy, and data-center demand into brisk top-line growth. Apple enters its earnings day with investors fixated on the strategic priorities of a new CEO, watching to see whether AI, hardware innovation, or services monetization takes center stage. Caterpillar, by contrast, has already delivered its punchline: a revenue beat, accelerating growth, and a growing reputation as 2026’s “accidental AI play” because every shiny new cloud server still requires concrete, steel, and reliable power.
In a market that has rewarded both tangible cash flows and intangible narratives, these two reports capture the moment’s nuance: investors want numbers, but they also want a story they can hold for more than a quarter. Apple’s challenge is to prove that a leadership handoff can coexist with renewed growth and competitive fire; Caterpillar’s is to show that a heavy-equipment champion can keep compounding like a software stock without flying too close to the cycle. For now, Wall Street seems willing to grant both companies the benefit of the doubt—so long as Apple’s new CEO sticks the landing and Caterpillar keeps proving that in an AI world, it pays to own the companies that move the earth beneath the cloud.
The Sources
Apple Earnings Become Sideshow With New CEO Ready to Grab Spotlight – Yahoo Finance https://finance.yahoo.com/markets/stocks/articles/apple-earnings-become-sideshow-ceo-090053017.htmlfinance.yahoo
Why CAT Stock Is 2026’s Accidental AI Play – Yahoo Finance https://finance.yahoo.com/markets/stocks/articles/why-cat-stock-2026-accidental-125706449.htmlfinance.yahoo
CAT Stock Forecast 2026: Can It Reach $960 With $51B Backlog and Data Center Demand? – MEXC Blog https://blog.mexc.com/finance/cat-stock-forecast-2026-960-target-51b-backlog-data-center/mexc
Caterpillar, Inc. vs. Apple, Inc. Sector Stock Comparison – Financhill https://financhill.com/compare/sectors/industrials/cat-vs-aaplfinanchill
Apple Reports First Quarter Results – Apple Newsroom https://www.apple.com/newsroom/2026/01/apple-reports-first-quarter-results/apple
Apple May Have Revealed a Big Earnings Clue by Announcing Tim Cook’s Successor – Yahoo Finance https://finance.yahoo.com/news/apple-may-have-revealed-a-big-earnings-clue-by-announcing-tim-cook-successor-182550256.htmlfinance.yahoo
Prediction: Apple Stock Will Flourish Under New CEO – Yahoo Finance https://finance.yahoo.com/markets/stocks/articles/prediction-apple-stock-flourish-under-180500238.htmlfinance.yahoo
Here’s What to Expect From Caterpillar’s Next Earnings Report – Yahoo Finance https://finance.yahoo.com/markets/stocks/articles/heres-expect-caterpillar-next-earnings-091625304.htmlfinance.yahoo
Caterpillar Is Set to Report Q1 Earnings: Buy, Sell or Hold the Stock? – Zacks https://www.zacks.com/stock/news/2909937/caterpillar-is-set-to-report-q1-earnings-buy-sell-or-hold-the-stockzacks
NASA is no longer just launching rockets; it is underwriting what amounts to a nuclear-powered freight line between planets. The agency’s Space Reactor 1 (SR1) program aims to send the world’s first interplanetary nuclear-powered spacecraft to Mars as early as the 2028 launch window, compressing risk, cost, and distance into a single, audacious bet on atomic propulsion.
In an era when investors parse every Federal Reserve syllable and debate whether artificial intelligence can justify its multiples, NASA is quietly building an asset class of its own: reliable, repeatable deep-space logistics. One might call it “infrastructure as a universe.”
From Fireworks to Freight: The Limits of Chemical Rockets
For decades, the standard Mars playbook has looked like a very expensive long-haul flight with no upgrade option. Launch during the narrow planetary alignment that appears once every two years, burn through a heroic amount of chemical fuel, coast for months, and hope the rover—roughly the size of an SUV—sticks the landing on the red planet
SpaceX’s Starship architecture illustrates both the promise and the pain of this model. A single Mars-bound Starship requires not just the largest booster ever built to reach low Earth orbit, but roughly 10 additional booster launches simply to refill its tanks in space. The upside: payload capacity equivalent to about 25 SUV-scale NASA rovers; the downside: a supply chain that makes even the most aggressive oil trader look conservative
Chemical propulsion, in other words, is the financial equivalent of a high-yield bond with a very tight window: big upside, but inflexible, fuel-heavy, and unforgiving.
Enter Space Reactor 1: A Modest Reactor With Immodest Ambitions
NASA’s answer is Space Reactor 1, or SR1, a nuclear-powered spacecraft designed to trade brute force for staying power. Instead of a gigantic, gigawatt-class reactor, SR1 runs on a compact nuclear fission system producing roughly 20 kilowatts of power—closer to a Home Depot backup generator than a Manhattan power plant, but in space, modest can be mighty
The reactor sits at the top of the spacecraft, feeding heat into a closed-loop heat-pipe system. A working fluid cycles through the reactor core, vaporizes, spins a turbine connected to an electric generator, cools back into liquid, and repeats—essentially a tiny, orbital utility that can run for years with no on-site maintenance until its nuclear fuel is spent. A radiation shield, long truss, and titanium radiators separate and cool the rest of the vehicle, protecting electronics the way a good compliance department protects traders from themselves
Why NASA Picked Ion Engines Over “Rocketship on Steroids”
Nuclear propulsion comes in two basic flavors, and NASA has, quite deliberately, chosen the slower, steadier one. Nuclear thermal engines promise roughly five times the efficiency of traditional rockets by heating cryogenic hydrogen directly in a reactor, turning it into exhaust gas without hauling heavy oxidizer.
SR1 instead uses nuclear-electric propulsion, pushing efficiency closer to ten times that of combustion rockets by using the reactor to generate electricity that feeds ion thrusters. Ion engines don’t explode; they persuade. Electricity energizes atoms in a compressed gas, then electromagnetic fields fling those charged particles out the back, creating a tiny but constant thrust.
It is the difference between a drag racer and a freight locomotive: the rocket wins the quarter mile, but the ion thruster wins the continent. Over long durations, that gentle, continuous push adds up to higher terminal speeds using a negligible amount of propellant, precisely the trait you want when your commute is measured in astronomical units, not exits.
The Mars Railroad: How SR1 Turns Deep Space Into a Shipping Lane
In a March 2026 presentation, NASA described SR1 as the first locomotive in a “railroad to Mars,” a metaphor that lands squarely in Wall Street’s wheelhouse. Like freight trains, nuclear-electric spacecraft don’t sprint; they haul heavy cargo efficiently, on predictable timetables, at low marginal cost.wsj+1
SR1 will not sprint to Mars in 45 days as some nuclear-thermal concepts advertise. Instead, it will take about a year to reach the planet, but will do so as the largest vehicle ever dispatched to the Martian system while sipping propellant so sparingly that the fuel bill would make an airline CFO weep with envy. The economic logic is intuitive: once the capital expenditure of a nuclear tug is made, the cost per kilogram of cargo drops sharply over repeated missions.
Investors used to thinking in terms of pipelines, railroads, and shipping lanes may recognize the playbook: build hard-to-replicate infrastructure, spread fixed costs across high throughput, and let the time value of reliability compound.
Recycling Moon Plans Into a Mars Engine
One of the more quietly sophisticated moves in SR1’s design is NASA’s decision to repurpose hardware originally built for a different, now-canceled project. The propulsion module that will accompany the nuclear system was initially developed for the Lunar Gateway, a planned moon-orbiting station in the early Artemis architecture.
When leadership shifted direction and the Gateway concept was shelved, NASA didn’t zero out the investment; it reallocated it. Habitation modules are being reimagined as parts of a lunar base, while the ion-based propulsion unit is being reconfigured as SR1’s workhorse bus—essentially turning a stranded asset into a growth vehicle.
On Wall Street, that’s called capital discipline. In Washington, it’s usually called a miracle.
Skyfall: Three Helicopters, No Lander, and a Real Estate Mission
When SR1 finally reaches Mars orbit, it will not deploy the usual parade of parachutes, retro-rockets, and landing platforms. Instead, it will release an entry capsule dubbed “Skyfall,” which will ride a heat shield into the Martian atmosphere, slow via aerobraking and supersonic parachute, then reveal not a rover, but three helicopter drones.
These aircraft are built on the same basic platform as the Ingenuity helicopter, which was originally intended as a short technology demo but ultimately flew 72 missions over nearly three years. This time the trio will separate at low altitude and fly themselves away from the falling hardware, bypassing the need for complex landing systems like airbags or sky cranes.
Their mandate is straightforward but critical: conduct high-resolution imaging and ground-penetrating radar surveys to identify flat landing zones and subsurface water ice deposits for future human missions. If Mars ever gets a mortgage market, these drones will have written the first appraisal reports.
Lunar Reactor 1 and the Compounding Curve of Atomic Power
SR1 is only the opening act in NASA’s nuclear portfolio. Around 2030, the agency intends to follow up with Lunar Reactor 1, a fission power source tailored to keep a moon base running through the lunar night—a two-week period when solar panels go dark and conventional equipment risks freezing.
By proving small reactors in cislunar space and then scaling up, NASA envisions multi-megawatt systems in the 2030s capable of supporting multi-year human missions to Mars. In financial terms, SR1 is the seed round, Lunar Reactor 1 the Series A, and the eventual Martian power grid the industrial IPO. The through line is a simple thesis: in the long run, energy density is destiny.
Risk, Regulation, and the “Nuclear” Word on the Prospectus
No one in Washington or on Wall Street is naïve about the optics of launching nuclear material into orbit. Nuclear propulsion and power in space remain tightly regulated, with rigorous safety protocols for both launch and on-orbit operations.wsj+1
Yet nuclear technology has powered naval submarines and aircraft carriers safely for decades, and small modular reactors are drawing renewed interest as part of terrestrial decarbonization strategies. In that context, SR1 looks less like a wild science experiment and more like a natural extension of a familiar, if emotionally loaded, technology stack.
Investors have long learned to live with risk profiles that include everything from derivative exposure to cybersecurity threats; radioisotope launch risk may soon simply join the checklist.
Why Markets Should Care: From Exploration to Cash Flows
At first glance, a nuclear-powered Mars freight train seems worlds away from quarterly earnings calls. But the industrial backbone required for SR1 and its successors touches a wide ecosystem: advanced materials, radiation-hardened electronics, precision manufacturing, electric propulsion, robotics, and eventually in-situ resource utilization on other worlds.redcliffetraining+1
As with earlier eras of infrastructure—railroads, telegraphs, undersea cables—the near-term returns may appear uneven, but the second-order effects can be vast. Better, cheaper, more reliable cargo delivery between Earth, the moon, and Mars is the sort of enabling technology that tends to spawn industries no one has a spreadsheet for yet.
In the meantime, NASA’s nuclear freight plan offers something Wall Street quietly craves in a noisy market: a long-duration, high-conviction thesis built not on hype, but on engineering that already works at smaller scale.
The Punchline: In Space, Efficiency Is the Ultimate Blue Chip
The subtle genius of SR1 is not that it promises science-fiction speeds, but that it embraces an almost old-fashioned discipline: move more, spend less, repeat often. In a field famous for spectacular one-off missions, NASA is designing a boringly reliable logistics asset—exactly the kind of thing that keeps both economies and civilizations expanding.
For now, the nuclear railroad to Mars is still laying its first stretch of track. But if the plan holds, future generations may look at chemical-only Mars missions the way modern traders look at paper tickets on an exchange floor: charming, nostalgic, and utterly inefficient.
This podcast examines the transformation of the global critical minerals supply chain at a time when resilience, innovation, and policy leadership are more urgent than ever. From mineral extraction and refinement, to government action and private sector innovation, each episode will bring you closer to the people and ideas shaping the future of resource security. Episode Summary: In this first episode of Season 2, Alberto Rosende sits down with Arnab Datta to unpack how the U.S. can move from critical mineral policy announcements to real market execution. Drawing on current initiatives like the MP Materials deal, Project Vault, and Project Forge, Arnab explains that the real vulnerability isn’t just processing dominance—it’s the lack of Western market infrastructure, including exchanges, benchmarks, liquidity, and financing tools that allow critical mineral markets to function independently of China. The episode ultimately argues that true supply chain resilience will come from pairing smart government tools—price floors, loans, equity, and permitting reform—with private-sector participation, creating the financial plumbing needed to build diversified, liquid, ex-China critical mineral markets at scale. Guest: Arnab Datta is the Managing Director of Policy Implementation at Employ America, where he leads the integration of policy and legal strategy across the organization’s advocacy efforts, and the Director of Policy Implementation at the Institute for Progress. His work focuses on translating complex ideas into actionable policy, including drafting legislative frameworks for initiatives like the Strategic Resilience Reserve. Datta previously served in the Office of Senator Michael Bennet, clerked for the Senate Judiciary Committee. He holds a Bachelor of Commerce from the University of Calgary, an MS in Foreign Service from Georgetown University, and a Juris Doctor from George Washington University, where he was a George Washington Scholar. His writing has appeared in major outlets including the New York Times, Financial Times, Washington Post, Slate, and Business Insider, and he has been featured on leading policy podcasts.. Host: Alberto Rosende is the President and CEO of Mi Global, Inc., a company dedicated to strengthening global resilience through the development of secure, transparent, and sustainable critical mineral supply chains. With decades of experience leading in the public and private sectors, Rosende brings a unique combination of strategic vision, operational discipline, and global perspective to the forefront of the minerals and energy sectors. Under his leadership, M2i Global has advanced initiatives and forged partnerships that align industry innovation with national security priorities.
Disclaimer: The views and opinions expressed in The Minerals and Metals Initiative podcast are solely those of the hosts and guests. They are provided for discussion and informational purposes only and do not represent the official policy, position, or recommendations of M2i Global, Inc. Any statements made should be understood as personal opinions, not factual claims, and should not be relied upon as investment, legal, or professional advice. While efforts are made to ensure accuracy, M2i Global makes no guarantees regarding completeness or reliability of the content.
All four Magnificent 7 companies reporting on April 29, 2026 exceeded Wall Street’s expectations, though market reactions were mixed as investors parsed massive AI infrastructure spending plans against revenue growth trajectories.
Microsoft: AI Revenue Surges 123% YoY
Microsoft delivered a decisive beat, reporting fiscal Q3 (ending March 31) EPS of $4.27 on revenue of $82.89 billion, surpassing analyst estimates of $4.04 EPS and $81.46 billion in revenue. Revenue grew 18% year-over-year, representing an acceleration from the 16% growth analysts had modeled.
The standout metric: Microsoft’s AI business reached a $37 billion annual revenue run rate, up 123% compared to the prior year. Azure cloud computing showed strong expansion, validating the company’s aggressive AI infrastructure investments. Despite the earnings beat, Microsoft shares fell over 1% in after-hours trading as investors digested the results following the stock’s worst quarterly performance since 2008.
Meta crushed expectations with Q1 EPS of $10.44 versus the $6.72 consensus estimate—a 55% beat—while revenue came in at $56.31 billion compared to the $55.45 billion forecast. Revenue grew 31% year-over-year, marking Meta’s fastest revenue expansion since 2021.
However, shares initially slid in after-hours trading after Meta raised its 2026 capital expenditure guidance to $115-$135 billion, up from prior estimates of $110-$115 billion. The increased spending reflects Meta’s commitment to AI infrastructure buildout, particularly for its Reality Labs division and AI training capabilities. Meta’s strong Q2 revenue guidance of $53.5-$56.5 billion—well above the $51.27 billion consensus—ultimately supported the stock.
Amazon: E-Commerce and AWS Drive Strong Performance
Amazon reported Q1 net sales of $181.5 billion, up 17% year-over-year (15% excluding favorable foreign exchange impacts), beating the $177.2 billion consensus estimate. Net income surged to $30.3 billion, or $2.78 per diluted share, far exceeding the $1.62-$1.63 EPS estimates and last year’s $1.59.
The headline net income figure included a pre-tax gain of $16.8 billion from Amazon’s investment in AI startup Anthropic. Operating income climbed to $23.9 billion, driven by strong performance across all three segments: North America ($8.3 billion), International ($1.4 billion), and AWS ($14.2 billion). AWS revenue growth of approximately 25% matched analyst projections of $36.79 billion. Amazon’s advertising business continued gaining traction with revenue reaching approximately $16.89 billion, up 21% year-over-year.
Alphabet: Cloud Margin Expansion Powers EPS Beat
Alphabet posted Q1 revenue of approximately $106.9-$107 billion, representing 18.5% year-over-year growth and exceeding the consensus estimate. While the company’s EPS of around $2.62-$2.68 came in slightly below last year’s $2.81 (down 4.6%), this was anticipated given the extraordinary 40% beat Alphabet delivered in Q1 2025.
The critical driver: Google Cloud revenue accelerated to approximately $18.4 billion, up 50% year-over-year from $17.66 billion in Q4 2025, with operating margins expanding dramatically from 20% to 27% since October 2025. This margin expansion drove consensus EPS expectations upward from $2.46 to $2.73 in recent months. Alphabet shares rose 0.36% heading into the report, reflecting investor confidence in the company’s AI monetization strategy through Gemini and Cloud services.
The Sources
[1] Microsoft’s earnings report lands after stock’s worst quarterly performance since 2008 https://www.cnbc.com/2026/04/29/microsoft-msft-q3-earnings-report-2026.html [2] Microsoft tops Q3 estimates, says AI business up 123% year over year https://finance.yahoo.com/sectors/technology/article/microsoft-tops-q3-estimates-says-ai-business-up-123-year-over-year-211358311.html [3] Microsoft Revenues Jump 18 Percent to $82.9 Billion in FY26Q3 https://www.thurrott.com/microsoft/335513/microsoft-revenues-jump-18-percent-to-82-9-billion-in-fy26q3 [4] Microsoft Posts Strong Expansion in Azure Cloud Computing Unit https://www.bloomberg.com/news/articles/2026-04-29/microsoft-posts-strong-expansion-in-azure-cloud-computing-unit [5] Meta looks to report fastest revenue growth since 2021 https://www.cnbc.com/2026/04/29/meta-q1-earnings-report-2026.html [6] Meta Platforms (META) Q1 2026: EPS $10.44 vs $6.72 est; Revenue https://www.gurufocus.com/news/8828137/meta-platforms-meta-q1-2026-eps-1044-vs-672-est-revenue-5631b-vs-5545b-est-still-135-undervalued-gf-score-97100 [7] Meta Platforms Earnings Preview: What to Watch in Q1 2026 Report https://finance.yahoo.com/markets/stocks/articles/meta-platforms-earnings-preview-watch-114500578.html [8] Meta Raises Outlook for Capital Spending in 2026; Shares Slide https://www.bloomberg.com/news/articles/2026-04-29/meta-raises-outlook-for-capital-spending-in-2026-shares-slide [9] Meta surges as revenue guidance outweighs big 2026 spending hike https://finance.yahoo.com/news/meta-stock-pops-revenue-guidance-215026394.html [10] Wall Street Sees 29% Upside for Meta While Retail Investors Turn … https://finance.yahoo.com/news/wall-street-sees-29-upside-110500705.html [11] Amazon Q1 earnings put the spotlight on AI spending and revenue https://finance.yahoo.com/sectors/technology/article/amazon-q1-earnings-put-the-spotlight-on-ai-spending-and-revenue-132251483.html [12] Amazon Q1 2026 Earnings Preview: 29 April Results | IG … https://www.ig.com/en/news-and-trade-ideas/_amazon-q1-earnings-preview–can-aws-and-ai-drive-growth-amid-co-260424 [13] Amazon will share its Q1 2026 earnings on April 29 https://www.aboutamazon.com/news/company-news/amazon-earnings-q1-2026-report [14] Amazon’s advertising business continues to gain traction https://www.marketwatch.com/livecoverage/amazon-earnings-stock-results-aws-guidance-ai/card/amazon-s-advertising-business-continues-to-gain-traction-8C9aCYQ1jndRaVpx0oak [15] Amazon earnings preview: Q1 2026 – S&P Global https://www.spglobal.com/market-intelligence/en/news-insights/research/2026/04/amazon-earnings-preview-q1-2026 [16] Alphabet earnings preview: Q1 2026 – S&P Global https://www.spglobal.com/market-intelligence/en/news-insights/research/2026/04/alphabet-earnings-preview-q1-2026 [17] Alphabet earnings on tap with Gemini, AI spending updates in focus … https://finance.yahoo.com/sectors/technology/article/alphabet-earnings-on-tap-with-gemini-ai-spending-updates-in-focus-with-stock-near-record-high-212244719.html [18] Alphabet Q1 2026 Earnings Preview | Results April 29 | IG AE – IG https://www.ig.com/ae/news-and-trade-ideas/alphabet-q1-2026-earnings-preview-260420 [19] Alphabet Q1 2026 Earnings Report – MarketBeat https://www.marketbeat.com/earnings/reports/2026-4-29-alphabet-inc-stock/ [20] Microsoft reports sinking Xbox revenue as its cloud business climbs https://www.theverge.com/tech/920785/microsoft-xbox-revenue-q3-2026-earnings [21] Amazon.com, Inc. – Amazon.com Announces First Quarter Results https://ir.aboutamazon.com/news-release/news-release-details/2026/Amazon-com-Announces-First-Quarter-Results/ [22] Microsoft perks up as Q3 results top estimates (MSFT:NASDAQ) https://seekingalpha.com/news/4581662-microsoft-perks-up-as-q3-results-top-estimates [23] Amazon set to report first-quarter earnings after the bell https://www.cnbc.com/2026/04/29/amazon-amzn-q1-earnings-report-2026.html [24] OpenAI Rattles Big Tech as Microsoft (MSFT), Amazon (AMZN) and Alphabet (GOOGL) Face Earnings Test https://www.tipranks.com/news/openai-rattles-big-tech-as-microsoft-msft-amazon-amzn-and-alphabet-googl-face-earnings-test [25] Amazon’s Oregon Footprint https://oregonbusiness.com/amazons-oregon-footprint/ [26] Microsoft Beats Fiscal Q3 Views On Cloud Computing, AI Strength https://www.investors.com/news/technology/microsoft-stock-msft-fiscal-q3-2026-earnings/ [27] Should You Buy, Sell or Hold Alphabet Stock Before Q1 Earnings? https://finance.yahoo.com/markets/stocks/articles/buy-sell-hold-alphabet-stock-181300754.html [28] Amazon Earnings Preview: AI Momentum In Focus, But This Number … https://www.investors.com/news/technology/amazon-stock-q1-2026-earnings-preview/ [29] Amazon Stock Plunges As Much As 10% After EPS Miss – Forbes https://www.forbes.com/sites/tylerroush/2026/02/05/amazon-shares-plunge-7-as-it-plans-200-billion-in-spending-for-2026-far-more-than-expected/ [30] How Much Amazon Stock Is Expected to Move After Earnings https://www.investopedia.com/amazon-stock-expected-to-move-after-earnings-q1-2026-11955138 [31] What To Expect From Alphabet’s (GOOGL) Q1 Earnings https://www.financialcontent.com/article/stockstory-2026-4-28-what-to-expect-from-alphabets-googl-q1-earnings [32] Buy Meta Stock After Strong Q4 Results & CapEx Hike? https://www.zacks.com/commentary/2825624/buy-meta-stock-after-strong-q4-results-capex-hike [33] Amazon Earnings Preview: All Eyes on AWS As Investors Want AI … https://www.businessinsider.com/amazon-q1-earnings-preview-aws-amzn-stock-ai-capex-2026-4 [34] Amazon.com (AMZN) Earnings Date and Reports 2026 – MarketBeat https://www.marketbeat.com/stocks/NASDAQ/AMZN/earnings/ [35] Alphabet (GOOGL) Will Report Q1 Earnings on April 29. Here Is What to Expect https://www.tipranks.com/news/alphabet-googl-will-report-q1-earnings-on-april-29-here-is-what-to-expect [36] Should You Buy, Sell or Hold Amazon Stock Before Q1 Earnings? https://www.zacks.com/stock/news/2908747/should-you-buy-sell-or-hold-amazon-stock-before-q1-earnings [37] Meta Stock: What Wall Street Expects From Q1 Earnings Wednesday https://www.mexc.com/news/1058955 [38] Meta (META) Q1 Earnings: What To Expect https://finance.yahoo.com/markets/stocks/articles/meta-meta-q1-earnings-expect-100455133.html [39] Alphabet Announces Date of First Quarter 2026 Financial Results … https://abc.xyz/investor/news/news-details/2026/Alphabet-Announces-Date-of-First-Quarter-2026-Financial-Results-Conference-Call-2026-18KYkWPpu7/default.aspx [40] Alphabet Earnings Preview: Q1 2026 – Seeking Alpha https://seekingalpha.com/article/4894829-alphabet-earnings-preview-q1-2026 [41] Meta Q1 2026 Earnings Preview: Results Due 29 April … – IG https://www.ig.com/uk/news-and-trade-ideas/meta-q1-earnings-preview–can-advertising-growth-support-massive-260423 [42] Alphabet (GOOGL) Earnings: Latest Report … – Public Investing https://public.com/stocks/googl/earnings [43] Meta to Announce First Quarter 2026 Results https://investor.atmeta.com/investor-news/press-release-details/2026/Meta-to-Announce-First-Quarter-2026-Results/default.aspx
FMC Corporation’s (NYSE: FMC) latest quarter reads less like a turnaround thriller and more like a carefully edited first chapter: the plot has stabilized, the characters know their lines, and Wall Street is quietly checking whether this agricultural chemist can indeed grow into its guidance. FMC’s stock is up over 7% in the aftermarket on Wednesday.
FMC’s Quarter: From Harvest Hangover to Normalcy
After a bruising 2025 marked by revenue compression, tariff noise, and farmer destocking, FMC’s first quarter landed roughly where management had steered expectations, with sales trending in line with a mid‑single‑digit decline and EBITDA pressured by one‑off costs and tariff headwinds. Order patterns have normalized in most key markets as distributors work through elevated inventories of FMC-branded products, a dynamic the company had flagged as a necessary precondition for any credible recovery story. While the quarter still reflects a crop protection industry working through excess supply and aggressive generic competition, FMC’s results sit toward the higher end of its own guidance corridor, a subtle but meaningful psychological beat for a stock that has spent the last three years in valuation purgatory.
Management’s full‑year 2026 revenue outlook of 3.6 billion to 3.8 billion dollars implies a modest top-line contraction versus last year, but the company frames this as a deliberate reset rather than a structural retreat. The narrative: let pricing on flagship molecules like Rynaxypyr drift lower post‑patent, accept near‑term margin trade‑offs, and then monetize a broader portfolio of biologicals, new chemistries, and precision-ag offerings once the industry shakes off its inventory hangover.
Guidance: When Lower Is Actually Higher
On paper, guiding to a 5 percent revenue decline at the midpoint is hardly the stuff of champagne at closing bell, but context matters in a sector still digesting years of overordering and falling crop prices. For FMC, reaffirming its full‑year outlook after a choppy 2025 signals that the company finally has a reasonably firm handle on channel inventory, pricing pressure, and tariff impacts that disproportionately hit the first quarter. Management expects approximately 20 million dollars in tariff-related headwinds for 2026 — the sort of number that keeps CFOs busy with spreadsheets but rarely changes the long‑term investment case when the balance sheet is being actively trimmed via asset sales and licensing.
Investors got an extra dose of comfort from the company’s willingness to outline its 2026 priorities early in the year, including a focus on debt reduction, portfolio optimization, and disciplined capital allocation. The message is almost old‑fashioned in its simplicity: fewer surprises, more cash flow, and a business that is willing to be a little boring on the income statement while it quietly renovates the product pipeline.
Dividend Discipline and the Art of Investor Signaling
In a market where dividend cuts are remembered longer than most M&A deals, FMC’s board chose the more subtle path: maintaining a modest regular quarterly dividend of 8 cents per share while it continues to prioritize balance sheet repair. At this level, the payout is less about offering aristocratic income and more about signaling that management believes cash flows, while constrained, are durable enough to support a consistent return of capital.
That restraint matters in context: FMC is coming off a period of sharply negative total shareholder return, with the stock down over 60 percent in the last year and more than 80 percent over three years as investors questioned whether the company’s moat around key chemistries had eroded for good. By keeping the dividend alive — but lean — FMC effectively seems to tell the market it will not spend its way back into favor; instead, it will earn it through operational execution and a cleaner balance sheet.
Portfolio, Patents, and Post‑Patent Pragmatism
If the last decade was defined by Rynaxypyr’s pricing power, the next decade will be defined by what FMC does after that era. Management is candid that pricing on its flagship insecticide will move lower as generics proliferate, and its 2026 guidance explicitly bakes in mid‑single‑digit price declines driven largely by that post‑patent strategy. Rather than treating this as an existential threat, FMC is leaning into a broader suite of crop protection tools, from new herbicides and fungicides to biological solutions intended to address regulatory and sustainability pressures on conventional chemistry.
The company plans nine new product launches in 2026, with seven in traditional crop protection and additional assets in the pipeline for 2027, a cadence designed to remind investors that FMC remains more research lab than liquidation story. In an industry increasingly driven by differentiation rather than sheer volume, the ability to roll out higher‑value formulations and digital decision support tools may matter more than the sticker price on any single legacy molecule.
Valuation: From Pesticide Giant to Patience Test
Wall Street, ever the careful reader of footnotes, is not yet ready to declare FMC a comeback stock, but the tone has shifted from “avoid” to “watch closely.” Analyst commentary frames the company as a “hold” for 2026: operational efficiency is improving, guidance is credible, and the product engine is very much alive, yet unresolved industry headwinds — generics, crop price volatility, and regulatory scrutiny — make an immediate re‑rating unlikely.
For long‑horizon investors, the set‑up is almost textbook: a sector-lagging share price, a solid but unspectacular dividend, a de‑risking balance sheet, and a pipeline that offers optionality if management executes. In the meantime, FMC’s latest quarter reads less like a heroic turnaround and more like what the market actually prefers after a rough cycle: a company that has stopped surprising on the downside and is quietly, methodically, earning back the right to be interesting again.
About FMC
FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC’s innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more.
Markets traded lower Wednesday, April 29, 2026, as investors braced for a critical one-two punch: the Federal Reserve’s rate decision and earnings from four of the Magnificent 7 tech giants after the closing bell. The S&P 500 closed at 7,135.95, down 0.04%, while the Nasdaq Composite edged .04% higher to 24,673.24, and the Dow Jones Industrial Average slipped .57% to 48,861.81. The 10-year Treasury yield climbed 1.47% to 4.418%, reflecting persistent concerns over inflation and geopolitical risk. the CBOE Volatility Index (VIX) rose 5.51% to $18.81.
Fed Decision: Rates on Hold, Powell’s Potential Swan Song
The Federal Open Market Committee kept interest rates unchanged in the 3.5%-3.75% range at 2:00 PM ET, exactly as markets anticipated. This meeting carries unusual significance as it could mark Chair Jerome Powell’s final policy decision before his term concludes in May. The Fed delivered its decision with the highest level of internal dissent since 1992, signaling deep divisions among policymakers navigating stubborn inflation and geopolitical energy shocks.
Without updated economic projections or a new dot plot—this wasn’t a quarterly forecasting meeting—market participants scrutinized Powell’s 2:30 PM press conference for clues about the Fed’s stance through mid-year. Traders have completely abandoned expectations for rate cuts in 2026, a stark shift from earlier positioning.
Macro Headwinds: Energy Crisis Clouds the Outlook
Crude Oil prices surged above $108/bbl per barrel for the first time in three weeks, driven by stalled U.S.-Iran peace negotiations and continued disruptions in the Strait of Hormuz. The breakdown in talks between Washington and Tehran has tightened global energy markets daily, with Iran’s Revolutionary Guard reportedly boarding cargo vessels in the critical shipping corridor. Oil prices have rallied over 55% since the Iran conflict began in late February, with Brent crude jumping 51% in March alone—one of the largest monthly surges on record.
Rising energy costs are reigniting inflation concerns just as the Fed seeks to maintain its restrictive policy stance. European markets reflected these anxieties, with oil and gas stocks leading sector gains (+0.9%) while broader risk sentiment remained subdued.cnbc+1
Magnificent 7 Earnings: The $670 Billion AI Capex Test
After the 4:00 PM ET close, Microsoft (MSFT), Meta Platforms (META), Alphabet (GOOGL), and Amazon (AMZN) reported first-quarter results, marking the most concentrated cluster of mega-cap tech earnings in market history. Apple (AAPL) rounds out the Mag 7 gauntlet Thursday, April 30.
The central question for investors: Can these four hyperscalers justify their staggering 2026 AI infrastructure commitments, which collectively approach $670 billion when annualized ? Meta guided capital expenditures of $115-$135 billion and the stock is down +6% in the aftermarket , Alphabet (GOOG) $175-$185 billion and is up +5% in the aftermarket, and Amazon roughly matching those levels and AMZN shares are trading off +3% in the aftermarket. Microsoft’s partnership with OpenAI adds further urgency to prove that Azure cloud growth is re-accelerating on AI demand. Microsoft (MSFT) shares are trading off +2% in the aftermarket.
Global Context: Central Banks and Volatility Ahead
Wednesday’s convergence of macroeconomic events and Mag 7 earnings created rare conditions for outsized volatility in both the S&P 500 and Nasdaq. Beyond the Fed, the Bank of Canada announced its rate decision, while inflation data from Germany, Australia, and Russia provided additional cross-currents.
With geopolitical energy risks escalating, the Fed navigating a potential leadership transition, and over $3 trillion in Mag 7 market cap reporting in a single afternoon, April 29 delivered the kind of market-defining moment that shapes investment narratives for quarters to come.
VP Watchlist Updates
Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.
FMC Corporation (NYSE:FMC, $$15.96, +8.94% in the aftermarket)
Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (April 21) 36-week tissue health and symptom data from patients in the highest dose cohort from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). Dr. James A. Helliwell, Chief Executive Officer of Eupraxia stated, “We are very pleased with the robust and sustained response in both tissue health and symptom data in the highest dose cohort at 36 weeks. This data is consistent with the compelling results we observed at earlier timepoints at this dose level, highlighting the potential to achieve both strong and durable responses after a single administration of EP-104GI. We are also reassured by the excellent safety outcomes across all doses in the trial as we continue to observe no indication of drug related SAEs or spikes in glucose or cortisol. We look forward to the results of the placebo-controlled Phase 2b portion of the study where the same dose is being further evaluated”.
Eupraxia recently co-hosted a Tribe Public www.TribePublic.com, CEO Presentation & Q&A Webinar event, Wednesday, April 1 titled “Turning EOE Into a Once-a-Year Appointment.” The event featured James A. Helliwell, M.D., Co‑founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX), who discusses the company’s precision drug‑delivery platform, its approach to Eosinophilic Esophagitis (EoE), and broader pipeline priorities, followed by a focused 5–10 minute Q&A. You may watch it now at this Youtube link.
Modular Medical (MODD, $4.17)
Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced that Jeb Besser, CEO of Modular Medical, will present at Tribe Public’s Webinar Presentation and Q&A Event titled “From FDA Wins to Scaling Manufacturing – What Investors Should Watch.” The event is scheduled to begin at 8 a.m. pacific / 11 a.m. eastern on Friday, May 1, 2026. To register to join the complimentary event, please visit the Tribe Public LLC at MODD-May-Watch.TribePublic.com.
Modular Medical announced (APRIL 19) the pricing of a registered direct offering consisting of 750,000 shares of the Company’s common stock at an offering price of $4.50 per share. The gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses. The Offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.
Modular Medical’s latest regulatory milestone upgrades the narrative: the company has now secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, moving from “launch‑ready” to “launch‑approved” in the heart of the fast‑growing diabesity market. The FDA has cleared Modular Medical’s Pivot patch pump as a tubeless, removable insulin delivery system, formally validating the device’s design and performance for commercial use in U.S. adults living with diabetes. The clearance converts what had been a Q1 2026 launch “subject to FDA response” into a tangible commercial pathway, giving the company permission to sell into an insulin pump market that has been estimated at roughly 8 billion dollars globally. Pivot is engineered as a simplified, two‑part patch pump with a 3‑milliliter removable reservoir, no need for battery recharging, and the ability to bolus without a dedicated controller, aiming squarely at patients who have stayed on multiple daily injections because traditional pumps felt too complex, cumbersome, or costly. By clearing Pivot, the FDA is effectively endorsing Modular Medical’s attempt to make advanced insulin delivery feel less like adopting a gadget and more like upgrading a daily habit.
The InterGroup Corporation (INTG, $42.23, +.14%)
InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.
Volato Group, Inc. (SOAR) & M2i Global, Inc. (MTWO, +12.61%)
M2i Global, Inc., a company specializing in the development and execution of a complete global value supply chain for critical minerals, announced (April 28), in connection with the the Agreement and Plan of Merger and Reorganization, dated as of July 28, 2025, by and among M2i Volato Group, Inc. (“Volato”) (NYSE American: SOAR), and Volato Merger Subsidiary, Inc., , that the sole holder of M2i’s Series A Super Voting Preferred Stock, entitled to 10,000 votes per share of voting stock, voted by written consent in favor of the Company’s merger with Volato whereby M2i will become a wholly-owned subsidiary of Volato. At the closing of the merger, the name of Volato will change to M2i Global.
flyExclusive (NYSE American: FLYX), the vertically integrated private aviation company, announced (March 25) two milestones in its proprietary technology development: the filing of a utility patent application for a novel aircraft schedule optimization architecture, and the availability of Contrails, its Flight Management System, to other Part 135 operators beginning in Q2 2026. Both announcements coincide with the company’s presence at the NBAA Schedulers & Dispatchers Conference 2026 in Cleveland. “We have spent years building flyExclusive into one of the most operationally capable private aviation companies in the country. Contrails is how we make that expertise available to the broader industry—and the intellectual property behind it reflects the depth of investment we have made in solving problems that matter to every serious operator. We believe the right technology, built by people who actually run flights, changes what is possible in this industry. Today we are unable to source lift for nearly 300 trip requests per day. We believe Contrails will allow us to address that demand far more efficiently—both within our own operation and through coordination with other operators—and that represents a material revenue opportunity for flyExclusive and for all participating operators.”
In an AI market obsessed with GPUs and stardust, Nokia (NOK) is quietly reminding investors that none of this magic moves without serious plumbing. While Nvidia (NVDA) prepares to headline its GTC 2026 “Woodstock of AI” showcase, the chip giant has already written a very real check to Nokia, committing a $1 billion investment to help rewire the world’s networks for 5G‑Advanced, 6G, and AI‑native workloads. The message is simple enough: GPUs may be the new rock stars, but networking is the stadium.
Nvidia delivered strong fourth-quarter results recently, posting revenue of $68.1 billion, well above analyst expectations. Looking ahead, the company projects $7.8 billion in revenue for the first quarter of 2026, reflecting continued robust demand for its AI chips even amid broader market headwinds.
Morgan Stanley (April 21) has adjusted its price target on McDonald’s (MCD) to $334, maintaining an Equal Weight stance on the stock . The firm’s analyst highlighted consumer strength heading into first-quarter results, noting that earnings quality will likely vary across the restaurant and food distribution landscape . While some operators may face headwinds, the underlying consumer backdrop remains robust, which could support McDonald’s performance as one of the industry’s quality players positioned to navigate the current environment .
Opendoor (OPEN, $5.58, +1.82%)
April 16, Opendoor Technologies Inc. (OPEN) announced that it will report first quarter 2026 financial results for the period ended March 31, 2026 following the close of the market on Thursday, May 7, 2026. On May 7, 2026, management will host our Financial Open House video livestream at 2:00 p.m. PT (5:00 p.m. ET) to discuss the company’s business and financial results. We invite shareholders to participate directly through Robinhood’s Say Technologies platform by visiting https://app.saytechnologies.com/opendoor-2026-q1
Opendoor continues to navigate a challenging housing backdrop characterized by still‑elevated mortgage rates and tight existing‑home inventories, which weigh on transaction volumes even as affordability slowly improves. The company’s focus on disciplined acquisition spreads, inventory turns, and ancillary services remains central to the investment debate as markets handicap the pace and magnitude of any 2026 housing recovery.
Tesla (TSLA, $372.80)
Reportedly, Tesla recently and unexpectedly swung to positive free cash flow in the first quarter, a neat trick for a company many on Wall Street still expected to be busily torching cash. The electric-vehicle maker has yet to fully open the spending spigots on artificial intelligence and added manufacturing capacity, suggesting the real splurge is still to come.
Reportedly, Ross Gerber of Gerber Kawasaki believes that combining Tesla and SpaceX could create a Berkshire Hathaway–style powerhouse focused on artificial intelligence.
Serina Therapeutics (NYSE: SER, $1.83)
Serina Therapeutics (NYSE: SER) (www.serinatx.com) seems to have have just traded itself into Wall Street’s good graces, pairing fresh capital with a late-session pop that suggests investors are finally starting to connect the dots between polymer chemistry and portfolio returns. In Huntsville, Alabama, Serina Therapeutics announced definitive agreements for a private placement of common stock and pre-funded warrants that could bring in up to 30 million dollars in gross proceeds. The first 15 million dollar tranche is expected to close on March 20, 2026, with a second tranche of up to 15 million dollars anticipated by April 30, 2026, subject to customary closing conditions.
What makes the deal stand out in a biotech tape crowded with discounts is the pricing: the securities are being sold at about 2.25 dollars per share, a roughly 68 percent premium to Serina’s March 17 closing price, signaling that insiders are willing to pay up for exposure to the company’s clinical agenda. The financing also adds board-level heft, with director Greg Bailey, M.D., stepping into a Co-Chairman role as he leads the investment, a move that effectively puts the capital and the governance on the same optimistic page. Learn more here.
Intel (INTC, $94.75, +12.06%)
FPT and Intel, a global leader in semiconductor and AI technologies, announced a strategic relationship to deliver an end-to-end AI-driven factory optimization solution. Powered by AI, simulation, and digital manufacturing technologies, the collaboration aims to reduce bottlenecks, accelerate decision-making and improve downtime recovery, facilitating the sector’s transition towards AI-driven, autonomous operations.
In a market that rarely rewards nostalgia, Nokia (NOK) is proving that reinvention—not remembrance—is the more durable currency. As of April 2026, the Finnish telecom stalwart is orchestrating a multi-front strategy spanning AI-driven networking, 6G exploration, and the ever-lucrative business of intellectual property licensing. The result is less “legacy handset maker” and more “infrastructure architect for the algorithmic age.”
If there’s a unifying theme, it’s this: networks are no longer just pipes—they’re becoming thinking systems.
AI Meets the Airwaves
Nokia’s latest collaboration with Orange and NVIDIA (NVDA) underscores a broader industry pivot toward AI-native telecom infrastructure. The trio is advancing AI-RAN (Artificial Intelligence Radio Access Networks), combining Nokia’s anyRAN 5G software with NVIDIA’s AI computing platforms.
The ambition is straightforward, if technically dense: make networks adaptive, predictive, and self-optimizing. In practical terms, that could mean dynamically allocating bandwidth based on real-time demand or preemptively resolving congestion before users notice. In investor terms, it signals a shift toward higher-margin, software-defined networking layers.
For Nokia, this is less about keeping up with the AI narrative and more about embedding itself within it—preferably at the infrastructure level, where switching costs are high and competitors are few.
A Long Game Called 6G
While much of the world is still digesting 5G, Nokia is already sketching the outlines of 6G. Its newly signed Memorandum of Understanding with Vodafone (VOD) New Zealand reflects both continuity and ambition.
The partnership aims to explore emerging 5G applications while laying groundwork for future 6G architectures. Think immersive connectivity, ultra-low latency systems, and networks that support everything from autonomous logistics to real-time digital twins.
The timeline for 6G commercialization remains comfortably distant—early 2030s by most estimates—but the signaling effect matters. In telecom, being early to define standards often translates into long-term strategic leverage.
Expanding the Map: Central Asia and Beyond
Not all innovation happens in Silicon Valley or Stockholm. Nokia’s strategic agreement with Freedom Telecom International highlights a quieter but significant push into Central Asia.
The partnership focuses on cloud infrastructure and AI-enabled network development, targeting regions where digital infrastructure is still catching up with demand. For Nokia, this represents both a growth opportunity and a chance to shape emerging markets before competitors fully arrive.
It’s a reminder that while headlines tend to follow developed markets, the next wave of network expansion may well be written elsewhere.
Monetizing the Invisible: Patents at Work
If networks are the visible layer of Nokia’s strategy, patents are the invisible engine quietly driving profitability. The company continues to expand its licensing footprint, including a recent agreement with Snap for video technology.
These deals rarely grab headlines, but they matter. Licensing revenues tend to be high-margin, recurring, and relatively insulated from the capital intensity of telecom infrastructure buildouts.
In effect, Nokia is monetizing decades of R&D—turning past innovation into present cash flow. It’s not glamorous, but on Wall Street, consistency often trumps excitement.
Governance, Dividends, and a Signal of Stability
At its April 9 Annual General Meeting, Nokia shareholders approved all board proposals, including dividend distributions and the appointment of Meredith Whittaker to the board.
The governance updates may lack the buzz of AI partnerships, but they reinforce a broader narrative: Nokia is positioning itself as both a growth story and a disciplined operator. The re-election of Deloitte Oy as auditor adds another layer of continuity, suggesting that while the company is evolving technologically, it remains steady operationally.
The Bigger Picture
Taken together, Nokia’s April developments paint a picture of a company threading multiple strategic needles at once: advancing AI capabilities, investing in next-generation connectivity, expanding geographically, and extracting value from intellectual property.
It’s a balancing act—part innovation lab, part infrastructure provider, part licensing powerhouse.
And while telecom has never been known for dramatic reinventions, Nokia’s current trajectory suggests something closer to a quiet transformation. Not flashy enough to dominate headlines, perhaps—but substantial enough to matter.
On a gray April morning better suited to defensive sectors than bold moves, Italy’s Chiesi Group decided to do the opposite and write a $1.9 billion check for KalVista Pharmaceuticals, a specialist in oral therapies for hereditary angioedema (HAE). The deal, struck at $27 per share in cash, hands KalVista holders an immediate all-cash exit at roughly a mid‑30s to 40% premium to the stock’s recent trading levels, depending on which look‑back you favor. In a market that has lately punished small- and mid-cap biotech for daring to fund science, a clean tender offer at a sizeable premium looks almost quaint—like a reminder that fundamentals, and not just factor rotations, occasionally still count.
The boards on both sides unanimously blessed the transaction, which will be executed via a tender offer followed by a back‑end merger once a majority of shares are tendered, with closing targeted for the third quarter of 2026, subject to customary conditions. For KalVista’s investors, the structure offers speed, certainty, and the kind of liquidity event that biotech pitch decks promise but rarely deliver on schedule.
Why Chiesi Is Paying Up: An Oral Answer to Injectables
Chiesi isn’t splurging for a “pipeline in a PowerPoint,” but for a commercial-stage rare immunology asset that has already cleared some of the industry’s most unforgiving hurdles. At the center of the transaction is sebetralstat, marketed in the U.S. as Ekterly, the first and only oral, on‑demand treatment approved for acute hereditary angioedema attacks in patients 12 and older. Historically, HAE patients had to rely on intravenous or subcutaneous therapies, often delaying treatment because starting an infusion in the middle of a workday—or a long-haul flight—is not most people’s idea of “on demand.”
Sebetralstat, an oral plasma kallikrein inhibitor, aims to change that calculus: patients can take a tablet at the onset of an attack, treating earlier and potentially reducing both severity and the broader burden of disease. Launched in the U.S. in mid‑2025, the drug generated about $49 million in sales in its first partial year on the market, giving Chiesi a real revenue line rather than an actuarial fantasy. A regulatory filing is planned in the U.S. to extend the label to children aged 2 to 11, with additional submissions underway in key international markets where approvals are already in place for older patients.
Rare Disease Ambition Meets B Corp Branding
Strategically, the purchase is Chiesi’s largest deal to date and a clear statement that the privately held, Parma‑based group intends to be more than a niche European player in rare immunology. Management has framed the acquisition as a cornerstone in its plan to reach roughly €6 billion in revenue by 2030, with sebetralstat expected to be a meaningful contributor to that target. The company, which carries certified B Corp status, has been leaning into the idea that “doing well by doing good” can also involve doing deals, provided they come with real patient impact and not just clever ESG slides.
By adding an established oral HAE franchise, Chiesi deepens its rare disease footprint and broadens its U.S. commercial infrastructure—long a missing piece for mid‑sized European biopharma groups hoping to compete with large‑cap peers. The transaction also reinforces a broader industry trend: as capital grows more expensive for development-stage biotech, well-capitalized pharma acquirers are stepping in to scoop up late‑stage and early commercial assets in narrowly defined, durable niches where payer resistance tends to be lower and patient need is stark.
KalVista Cashes Out, but Its Science Trades Up
For KalVista, the acquisition is the kind of endgame that biotech business plans are written around: a focused, oral small‑molecule platform aimed at plasma kallikrein and related proteases, validated through late‑stage data and now plugged into a global commercial engine. The company had built its reputation on designing orally available kallikrein inhibitors for HAE and other indications, with the KONFIDENT trial program establishing sebetralstat’s efficacy and safety profile as an on‑demand therapy in adolescent and adult patients. Positive Phase 2 and confirmatory data showed clinically meaningful reductions in attack symptoms and improved patient‑reported outcomes, with a tolerability profile consistent with chronic use, an important consideration in a disease defined by unpredictable flares.
Shareholders, meanwhile, are exiting at a valuation that significantly exceeds KalVista’s pre‑deal market cap—which hovered under $1 billion—highlighting how much of the value in this story had yet to be priced in by public markets. The roughly 36–40% premium to recent trading levels underscores a perennial reality of biotech: the cost of capital can be so high that, for many platforms, the cheapest path to global scale is ultimately via someone else’s balance sheet.
What Investors Will Watch Next
Once the headlines fade, several questions will shape how this deal is judged in hindsight. First, can Chiesi accelerate sebetralstat’s global ramp, especially as it broadens the label to younger children and deepens penetration in markets where injectable competitors are entrenched but not beloved? Second, how effectively will Chiesi leverage KalVista’s discovery engine beyond HAE, potentially extending its kallikrein expertise into adjacent indications where oral, rapid‑onset therapies could similarly displace infusions?
Finally, there is the broader strategic ledger: does a $1.9 billion check in 2026 look prescient or pricey when we get to 2030 and tally Chiesi’s rare disease revenue against its ambitions? For now, in a market still recalibrating its appetite for risk, the transaction reads like a controlled, data‑driven swing rather than a speculative lunge—a reminder that in rare diseases, a well‑timed tablet can be worth more than a thousand injections, and occasionally, more than a billion dollars.
The Sources
Chiesi Group – “Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio” (official press release)chiesi+1
In a market where capital efficiency has become the new currency of credibility, Eli Lilly & Co. (LLY) appears to be writing a decidedly modern playbook for growth—one acquisition at a time. The Indianapolis-based pharmaceutical heavyweight has quietly assembled a portfolio of emerging biotech innovators, targeting companies like Kelonia Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, and Ventyx Biosciences. The strategy is less about headline-grabbing megadeals and more about precision engineering in drug development.
If Big Pharma once behaved like a department store—buying in bulk and sorting later—Lilly is operating more like a boutique investor, curating high-conviction assets with scientific specificity.
Precision Over Scale: The Kelonia and Ajax Play
Lilly’s moves toward Kelonia Therapeutics and Ajax Therapeutics reflect a growing emphasis on next-generation modalities. Kelonia, known for its work in targeted genetic medicines, fits neatly into Lilly’s ambitions in gene editing and delivery platforms—a space where success hinges as much on precision as it does on promise.
Ajax Therapeutics, meanwhile, brings a focused approach to hematologic malignancies. Its assets, built on insights into cancer genetics, complement Lilly’s oncology pipeline without the usual integration headaches that come with broader acquisitions. In essence, Lilly is buying expertise, not just assets—a distinction that investors increasingly reward.
Centessa: A Platform Bet With Optionality
Centessa Pharmaceuticals represents a slightly different flavor of dealmaking. Structured as a collection of “asset-centric” programs, Centessa offers Lilly a diversified pipeline wrapped in a single corporate entity. It’s a model that mirrors venture capital logic—multiple shots on goal, each with independent upside.
For Lilly, the appeal is clear: access to a range of therapeutic candidates without committing to a single binary outcome. In a sector where clinical trial results can swing valuations overnight, optionality isn’t just attractive—it’s essential.
Ventyx Biosciences and the Immunology Frontier
Ventyx Biosciences adds another dimension to Lilly’s expansion, particularly in immunology and inflammation. As autoimmune diseases continue to represent a significant unmet need—and a lucrative market—Ventyx’s small-molecule therapies offer scalability and commercial potential.
This aligns with Lilly’s broader push beyond its well-publicized success in diabetes and obesity treatments. While GLP-1 therapies have captured investor imagination (and waistlines), the company’s pipeline diversification suggests a leadership team keenly aware that today’s blockbuster can quickly become tomorrow’s baseline.
A Calculated Bet on Biotech’s Reset
These acquisitions come at a time when the biotech sector is still recalibrating from its pandemic-era exuberance. Valuations have compressed, funding has tightened, and many early-stage companies find themselves more open to partnership—or acquisition—than they might have been just a few years ago.
Lilly’s approach capitalizes on this environment without appearing opportunistic. By targeting companies with strong science but limited commercial infrastructure, it positions itself as both a buyer and a builder.
The Bigger Picture for Investors
For investors, Lilly’s acquisition strategy underscores a broader shift in how large pharmaceutical companies are managing innovation risk. Rather than relying solely on internal R&D or transformative mergers, the focus has turned to modular growth—acquiring targeted capabilities that can be integrated with relative ease.
It’s a strategy that may lack the drama of blockbuster deals, but it offers something arguably more valuable: consistency.
And in today’s market, consistency—like a well-timed clinical success—is worth its weight in gold.
The Sources
Fierce Biotech – “After Lilly-Kelonia deal, are any in vivo biotechs left to buy?” https://www.fiercebiotech.com/biotech/frenzied-feeding-playing-defense-and-disruption-lillys-kelonia-acquisition-and-future-vivo
STAT News – “Eli Lilly’s $3.25B acquisition of Kelonia Therapeutics caps startup’s…” https://www.statnews.com/2026/04/20/kelonia-therapeutics-eli-lilly-slide-deck-memo/
CNBC – “Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7B” https://www.cnbc.com/2026/04/20/eli-lilly-to-acquire-cancer-drug-maker-kelonia.html
Crunchbase News – “Lilly Acquiring Kelonia In Largest Funded Biotech Startup Purchase” https://news.crunchbase.com/ma/lilly-acquiring-kelonia-cancer-treatment-biotech-startup/
Onco’Zine – “Eli Lilly Moves Boldly into Next-Generation Blood Cancer with $2.3B Ajax Deal” https://oncodaily.com/techology/lilly-492759
The New York Times – “Eli Lilly Will Buy a Narcolepsy Drug Developer for $6.3 Billion” https://www.nytimes.com/2026/03/31/business/eli-lilly-narcolepsy-centessa.html
PR Newswire – “Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory…” https://www.prnewswire.com/news-releases/lilly-to-acquire-ventyx-biosciences-to-advance-oral-therapies-targeting-inflammatory-me…
Investing.com – “Ventyx Biosciences completes $1.2 billion acquisition by Eli Lilly, delists from Nasdaq” https://www.investing.com/news/sec-filings/ventyx-biosciences-completes-12-billion-acquisition-by-eli-lilly-delists-from-nasdaq-…
Fierce Biotech – “Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax” https://www.fiercebiotech.com/biotech/lilly-continues-ma-streak-23b-deal-next-gen-jak-inhibitor-biotech-ajax
CNBC – “Eli Lilly to acquire Centessa and sleep disorder drugs” https://www.cnbc.com/2026/03/31/eli-lilly-to-acquire-centessa-and-sleep-disorder-drugs.html
